Acute myeloid leukemia in the elderly: A review;Leucémies aiguës myéloïdes du sujet âgé: Mise au point

Bulletin du Cancer

Volumn 88, Issue 2, 2001, Pages 143-154

  Thomas, X ^a   Belhabri, A ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Chemotherapy; Elderly; Prognosis

Indexed keywords

AMIFOSTINE; AMSACRINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOFOS; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; INTERCALATING AGENT; MITOXANTRONE; TIOGUANINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; HEMATOPOIETIC STEM CELL; HUMAN; INCIDENCE; KARYOTYPE; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; INTERCALATING AGENTS; LEUKEMIA, MYELOID; MIDDLE AGED; PROGNOSIS;

EID: 0035068306     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Acute myeloblastic leukaemia in the elderly
2. Serum LDH as a predictor of clinical outcome in acute myelogenous leukemia of the elderly
3. Treatment of acute myeloid leukemia in elderly patients
4. Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients
5. Intensifed induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
6. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial
7. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study
8. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B
9. A phase Ill trial comparing idarubicin and daunorubicin combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study
10. Intensive postremission chemotherapy in adults with acute myeloid leukemia
11. Treatment of AML in the elderly: Full dose versus reduced dose induction treatment
12. Dose intensification in acute myeloid leukemia: Greater effectiveness at lower cost: Principal report of the Medical Research Council's AML9 study
13. A randomized, double-blind, placebo-controlled, Phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
14. De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence, treatment, and outcome
15. Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia
16. Treatment of newly diagnosed acute myelogenous leukemia in patients aged 80 years and above
17. Clonal haemopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes
18. Epidemiology of acute myelogenous leukemia
19. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome
20. Clonal development, stem cell differentiation and clinical remission in acute non-lymphocytic leukemia
21. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A report on 283 cases
22. Diagnostic criteria for hypoplastic acute leukemia: A clinical entity distinct from overt acute leukemia and myelodysplastic syndrome
23. Proposals for the classification of the acute leukaemias
24. A variant form of hypergranular promyelocytic leukemia
25. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
26. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): A report of the French-American-British Cooperative Group
27. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0)
28. Biological features of acute myeloid leukemia in the elderly
29. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype
30. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocyric leukemia
31. Management of acute myeloid leukemia in elderly patients
32. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
33. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program
34. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia
35. Difference between young and old patients in characteristics of leukemia cells
36. Multivariate analysis of prognostic factors in acute myeloid leukemia: Value of clonogenic leukemia properties
37. Prognostic factors in elderly patients with acute myeloid leukaemia: Development of a model to predict survival
38. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly
39. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9301)
40. A randomized trial of high- versus standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia
41. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
42. The significance of the achievement of complete response in elderly patients with acute myeloblastic leukemia
43. Acute myeloblastic leukemia in elderly patients: Treatment and prognostic factors
44. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B
45. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study
46. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)
47. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
48. A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia
49. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
50. A prospective randomized trial of idarubicin versus daunorubicin in combination with chemotherapy for acute myelogenous leukemia of the age group 55 to 75
51. A phase III study of daunorubicin versus idarubicin versus mitoxantrone for older adult patients (> 55 yrs) with acute myelogenous leukemia (AML): A study of the Eastern Cooperative Oncology Group (E3993)
52. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia
53. Validation of a model to predict survival in elderly patients with acute myeloid leukaemia
54. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide
55. Multicenter randomized phase II trial of idarubicin versus mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral stem cell transplantation in elderly patients with acute myeloid leukemia
56. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly
57. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
58. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study
59. 2 improves response and survival in elderly patients with AML
60. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: A Leukemia Intergroup study
61. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia
62. High-dose AraC (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: A pilot multicentric study by the Italian Cooperative Group GIMEMA
63. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
64. High-dose ara-C in older adults with acute leukemia
65. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study
66. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
67. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia
68. Neutropenia and neoplasia and overview of the pharmacoeconomics of sargramostim in cancer therapy
69. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adults patients (> 55 to 70 years of age) with acute myelogenous leukemia: An Eastern Cooperative Oncology Group (E1490) trial
70. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia
71. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo myeloid leukemia
72. Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia
73. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia
74. Therapy of acute myelogenous leukemia in patients over the age of 50: A randomized Southeastern Cancer Study Group trial
75. Acute myelogenous leukemia: Maintenance chemotherapy after early consolidation treatments does not prolong survival
76. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group
77. Mini-allografts: Ongoing trials in humans
78. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
79. Acute promyelocytic leukemia (APL) in the elderly: Results of the AIDA protocol
80. Low-dose cytarabine versus intensive chemothetapy in the treatment of acute non-lymphocytic leukemia in the elderly
81. Does treatment with AraC in low dosage cause differentiation of leukemic cells?
82. Low-dose cytosine arabinoside treatment for acute nonlymphocyric leukemia in elderly patients
83. Low-dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemia in the elderly
84. Low-dose AraC therapy for acute myelogenous leukemia in elderly patients
85. Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?. A report on 77 cases
86. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly
87. A predictive model response to low dose Ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukaemia
88. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphoblastic leukemia and myelodysplastic syndromes
89. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: A novel approach
90. Pilot study of 5-aza-2'-deoxycytidine (decitabine) in the treatment of poor prognostic acute myelogenous leukemia patients: Preliminary results
91. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
92. Oral idarubicin in adult acute non lymphocytic leukemia in poor risk patients
93. Treatment of acute myeloid leukemia with oral idarubicin as single agent
94. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
95. Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients
96. Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients
97. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acte myeloid leukaemia in the elderly: A report of toxicity and efficacy
98. A pilot study of oral idarubicin and etoposide in elderly patients with AML
99. Oral induction and consolidation of acute myeloid leukemia with eroposide, 6-thioguanine and idarubicin (ETI) in elderly patients: A randomized comparison with 5-days TAD
100. Treatment of patients over 50 years of age with acuta myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincrisrine, and prednisone (ROAP)
101. Acute nonlymphocytic leukemia in the elderly: Results of a retrospective study
102. Mitoxantrone and cytosine arabinoside as treatment of acute myeloblastic leukemia in older patients
103. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
104. Acute myeloid leukemia (AML) in the elderly: Aggressive versus non aggressive therapy. A report of the Gimema archive of adult acute leukemia
105. Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis
106. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
107. Preliminaty report of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients ≥ 60 years of age with acute myelogenous leukemia in first relapse
108. Interleukin-2 in acute leukemia
109. Histamine and interleukin-2 in acute myelogenous leukemia
110. Flt3 ligand induces tumor regression and anti-tumor immune responses in vivo
111. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study
112. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)
113. A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC833: Southwest Oncology Group Study # 9617
114. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) ≥ 60 years (CALGB 9720)
115. Amifostine cytoprotection and dose escalation of idarubicin in elderly high risk patients with acute myelogenous leukemia
116. Treatment of acute myelogenous leukemia in the elderly with daunorubicin + ara-C combined with amifostine ('AMI-DA'): Results of a pilot study
117. Phase I study of liposomal daunorubicin in patients with acute leukemia
118. Daunorubicin uptake by leukemic cells: Correlations with treatment outcome and mdr1 expression
119. Treatment of acute myelogenous leukaemia in patients aged 50-65: Idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course